Serum HER-2/neu as predictive factor in breast cancer patients treated with Herceptin;Prediktivní význam sérového HER-2/neu u nemocných s karcinomem prsu léčených Herceptinem

Klinicka Onkologie

Volumn 18, Issue 1, 2005, Pages 23-26

  Simickova M ^a   Petrakova K ^a   Pecen, L ^b   Nekulova M ^a   Frgala, T ^a   Nenutil, R ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b INSTITUTE OF ANALYTICAL CHEMISTRY   (Czech Republic)

Author keywords

Breast cancer; Follow up; Herceptin; Serum HER 2 neu

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; EVALUATION; FOLLOW UP; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; LONG TERM CARE; MOLECULAR DYNAMICS; ONCOGENE; TREATMENT FAILURE; VALIDATION PROCESS;

EID: 20444471065     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, K. J. Bloom: The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. The Oncologist 8, 2003, 307-325.
2. W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, C. H. Price: Potential utility of serum HER-2/neu oncoprotein concentration in patients with breast cancer. Clin. Chem. 49, 2003, 1579-1598.
3. D. Lüftner, C. Luke, K. Possinger: Serum HER-2/neu in the management of breast cancer patients. Clin. Biochem. 36, 2003, 233-240.
4. T. I. Andersen, E. Paus, J. M. Nesland, S. J. McKenzie, A. L. Borrensen: Detection of c-erbB-2 related protein in sera from breast cancer patients. Acta Oncol. 34, 1995, 499-504.
5. T. Fehm, P. Maimonis, A. Kalatinic, W. Jager: The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55, 1998, 3-38.
6. M. Krainer, T. Brodowitz, R. Zellinger, C. Wiltschke, C. Schoelten, M. Seifert et al.: Tissue expression and serum levels of HER-2neu in patients with breast cancer. Oncology 54, 1997, 475-481.
7. T. Fehm, G. Gebauer, W. Jager: Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res. Treat. 75, 2002, 97-106.
8. A. Lipton, S. M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, H. A. Harvey, C. Brady, C. M. Nalin, M. Dugan, W. Carney, J. Allard: Elevated serum HER-2/neu levels predict decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 26, 2002, 1467-1472.
9. J. Shou, S. Massarweh, C. K. Osborne, A. E. Wakeling, S. Ali, H. Weiss, R. Schiff: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96, 2004, 926-35.
10. W. J. Kostler, B. Schwab, C. Singer, R. Neumann, E. Marton, T. Brodowitz, S. Tomek, G. Steger, M. Krainer, C. Wiltschke, C. Zelinski: Predictive value of serum HER-2/neu extracellular domain (ECD) during trastuzumab-based therapy in patients with breast cancer. Proc. Am. Assoc. Cancer Res., Abstract 2437, 43, 2002, 201.
11. J. Esteva, V. Valero, D. Booser, L. T. Guerra, J. L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. A. Ffritsche, N. Sneige, T. L. Smith, G. N. Hortobagyi: Phase II study of weekly Docetaxel and Trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 2002, 1800-1808.
12. M. Hoopmann, R. Neumann, T. Tanasale T. Schöndorf: HER 2/neu determination in blood plasma of patients with HER 2/neu overexpressing metastasized breast cancer: A longitudinal study. Anticancer Res. 22, 2002, 1031-1034.
13. H. J. Burstein, L. N. Harris, P. K. Marcom, R. Lambert-Falls, K. Havlin, B. Overmoyer, R. J. Friedlander, J. Gargiulo, R. Strenger, C. L. Vogel, P. D. Ryan, M. J. Ellis, R. A. Nunes, C. A. Bunnel, S. M. Campos, M. Hallor, R. Gelman, E. P. Winner: Trastuzumab and Vinorelbin as first-line therapy for HER-2_overexpressing metastatic breast cancers: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. 21, 2003, 2889-2895.